HER2 Testing Characteristics Can Predict Residual Cancer Burden following Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Tamera J LillemoeMara RendiMichaela L TsaiMonica KnaackRina YaroshErin GrimmBarbara SusnikJanet KruegerSusan OletKaren K Swenson

Published in: International journal of breast cancer (2021)

HER2+ characteristics show differing response to therapy despite all being categorized as positive; tumors with less than 100% IHC 3+ staining, lower HER2 FISH copies, and lower HER2/CEP17 ratios resulted in higher RCB scores.

Keyphrases

neoadjuvant chemotherapy
positive breast cancer
locally advanced
lymph node
papillary thyroid
sentinel lymph node
squamous cell carcinoma
squamous cell
risk factors
early stage
lymph node metastasis
cell therapy
flow cytometry
smoking cessation
childhood cancer